Cargando…

Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity

The aggregation of amyloidogenic polypeptides is strongly linked to several neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Conformational antibodies that selectively recognize protein aggregates are leading therapeutic agents for selectively neutralizing toxic aggregate...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Alec A., Smith, Matthew D., Zhang, Yulei, Makowski, Emily K., Gerson, Julia E., Ionescu, Edward, Starr, Charles G., Zupancic, Jennifer M., Moore, Shannon J., Sutter, Alexandra B., Ivanova, Magdalena I., Murphy, Geoffrey G., Paulson, Henry L., Tessier, Peter M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081927/
https://www.ncbi.nlm.nih.gov/pubmed/33675750
http://dx.doi.org/10.1016/j.jbc.2021.100508
_version_ 1783685737208610816
author Desai, Alec A.
Smith, Matthew D.
Zhang, Yulei
Makowski, Emily K.
Gerson, Julia E.
Ionescu, Edward
Starr, Charles G.
Zupancic, Jennifer M.
Moore, Shannon J.
Sutter, Alexandra B.
Ivanova, Magdalena I.
Murphy, Geoffrey G.
Paulson, Henry L.
Tessier, Peter M.
author_facet Desai, Alec A.
Smith, Matthew D.
Zhang, Yulei
Makowski, Emily K.
Gerson, Julia E.
Ionescu, Edward
Starr, Charles G.
Zupancic, Jennifer M.
Moore, Shannon J.
Sutter, Alexandra B.
Ivanova, Magdalena I.
Murphy, Geoffrey G.
Paulson, Henry L.
Tessier, Peter M.
author_sort Desai, Alec A.
collection PubMed
description The aggregation of amyloidogenic polypeptides is strongly linked to several neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Conformational antibodies that selectively recognize protein aggregates are leading therapeutic agents for selectively neutralizing toxic aggregates, diagnostic and imaging agents for detecting disease, and biomedical reagents for elucidating disease mechanisms. Despite their importance, it is challenging to generate high-quality conformational antibodies in a systematic and site-specific manner due to the properties of protein aggregates (hydrophobic, multivalent, and heterogeneous) and limitations of immunization (uncontrolled antigen presentation and immunodominant epitopes). Toward addressing these challenges, we have developed a systematic directed evolution procedure for affinity maturing antibodies against Alzheimer’s Aβ fibrils and selecting variants with strict conformational and sequence specificity. We first designed a library based on a lead conformational antibody by sampling combinations of amino acids in the antigen-binding site predicted to mediate high antibody specificity. Next, we displayed this library on the surface of yeast, sorted it against Aβ42 aggregates, and identified promising clones using deep sequencing. The resulting antibodies displayed similar or higher affinities than clinical-stage Aβ antibodies (aducanumab and crenezumab). Moreover, the affinity-matured antibodies retained high conformational specificity for Aβ aggregates, as observed for aducanumab and unlike crenezumab. Notably, the affinity-maturated antibodies displayed extremely low levels of nonspecific interactions, as observed for crenezumab and unlike aducanumab. We expect that our systematic methods for generating antibodies with unique combinations of desirable properties will improve the generation of high-quality conformational antibodies specific for diverse types of aggregated conformers.
format Online
Article
Text
id pubmed-8081927
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Biochemistry and Molecular Biology
record_format MEDLINE/PubMed
spelling pubmed-80819272021-05-06 Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity Desai, Alec A. Smith, Matthew D. Zhang, Yulei Makowski, Emily K. Gerson, Julia E. Ionescu, Edward Starr, Charles G. Zupancic, Jennifer M. Moore, Shannon J. Sutter, Alexandra B. Ivanova, Magdalena I. Murphy, Geoffrey G. Paulson, Henry L. Tessier, Peter M. J Biol Chem Research Article The aggregation of amyloidogenic polypeptides is strongly linked to several neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Conformational antibodies that selectively recognize protein aggregates are leading therapeutic agents for selectively neutralizing toxic aggregates, diagnostic and imaging agents for detecting disease, and biomedical reagents for elucidating disease mechanisms. Despite their importance, it is challenging to generate high-quality conformational antibodies in a systematic and site-specific manner due to the properties of protein aggregates (hydrophobic, multivalent, and heterogeneous) and limitations of immunization (uncontrolled antigen presentation and immunodominant epitopes). Toward addressing these challenges, we have developed a systematic directed evolution procedure for affinity maturing antibodies against Alzheimer’s Aβ fibrils and selecting variants with strict conformational and sequence specificity. We first designed a library based on a lead conformational antibody by sampling combinations of amino acids in the antigen-binding site predicted to mediate high antibody specificity. Next, we displayed this library on the surface of yeast, sorted it against Aβ42 aggregates, and identified promising clones using deep sequencing. The resulting antibodies displayed similar or higher affinities than clinical-stage Aβ antibodies (aducanumab and crenezumab). Moreover, the affinity-matured antibodies retained high conformational specificity for Aβ aggregates, as observed for aducanumab and unlike crenezumab. Notably, the affinity-maturated antibodies displayed extremely low levels of nonspecific interactions, as observed for crenezumab and unlike aducanumab. We expect that our systematic methods for generating antibodies with unique combinations of desirable properties will improve the generation of high-quality conformational antibodies specific for diverse types of aggregated conformers. American Society for Biochemistry and Molecular Biology 2021-03-04 /pmc/articles/PMC8081927/ /pubmed/33675750 http://dx.doi.org/10.1016/j.jbc.2021.100508 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Desai, Alec A.
Smith, Matthew D.
Zhang, Yulei
Makowski, Emily K.
Gerson, Julia E.
Ionescu, Edward
Starr, Charles G.
Zupancic, Jennifer M.
Moore, Shannon J.
Sutter, Alexandra B.
Ivanova, Magdalena I.
Murphy, Geoffrey G.
Paulson, Henry L.
Tessier, Peter M.
Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity
title Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity
title_full Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity
title_fullStr Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity
title_full_unstemmed Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity
title_short Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity
title_sort rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081927/
https://www.ncbi.nlm.nih.gov/pubmed/33675750
http://dx.doi.org/10.1016/j.jbc.2021.100508
work_keys_str_mv AT desaialeca rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity
AT smithmatthewd rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity
AT zhangyulei rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity
AT makowskiemilyk rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity
AT gersonjuliae rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity
AT ionescuedward rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity
AT starrcharlesg rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity
AT zupancicjenniferm rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity
AT mooreshannonj rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity
AT sutteralexandrab rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity
AT ivanovamagdalenai rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity
AT murphygeoffreyg rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity
AT paulsonhenryl rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity
AT tessierpeterm rationalaffinitymaturationofantiamyloidantibodieswithhighconformationalandsequencespecificity